# A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

> **NCT07169578** · PHASE3 · RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 800 (estimated)

## Conditions studied

- Alzheimers Disease

## Interventions

- **DRUG:** Trontinemab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07169578
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-17
- **Primary completion:** 2028-06-07
- **Final completion:** 2028-06-07
- **Target enrollment:** 800 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07169578

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07169578, "A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT07169578. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*